NeOnc Technology Announces $16M PIPE Financing Led by $10M Capital Investment | NewsOut

Biotech and healthcare investors: NeOnc Technology, a multi–Phase 2 clinical-stage biopharmaceutical company developing therapies for central nervous system cancers, has entered into a PIPE financing expected to generate up to $16 million in gross proceeds.

Reporting from the New York Stock Exchange, Jane King explains that the offering includes common stock and five-year warrants, with proceeds intended for debt repayment, working capital, and corporate purposes. The PIPE is led by a $10 million investment from Capital Management, signaling institutional confidence in NeOnc’s therapeutic pipeline and long-term strategy.

#NeOnc
#NeOnc Technology
#BiotechNews
#PIPEFinancing
#CNSCancer
#ClinicalStageBiotech
#HealthcareInvesting
#CapitalMarkets
#DrugDevelopment
#InstitutionalInvestment
#JaneKing
#NewsOut
#NYSE